US 12233104
Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
granted A61KA61K38/2013A61K38/2086
Quick answer
US patent 12233104 (Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist) held by Nektar Therapeutics expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Nektar Therapeutics
- Grant date
- Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K38/2013, A61K38/2086, A61K47/60, A61P